BioCell Technology's new I-Sabi research white paper - Booth #807
March 1, 2010
![BioCell Technology's new I-Sabi research white paper - Booth #807 BioCell Technology's new I-Sabi research white paper - Booth #807](https://eu-images.contentstack.com/v3/assets/blt09e5e63517a16184/bltafc06db067aebac6/64cbf83cdb0bcc7a8de33eaa/NewHopeNetwork_Horizontal_RGB.png?width=1280&auto=webp&quality=95&format=jpg&disable=upscale)
BioCell Technology has issued a white paper on its patent-pending i-Sabi dietary ingredient, which is made from the plant rhizome of Wasabia japonica, more commonly known as wasabi. Wasabi contains a wide spectrum of bioactivities, including antioxidant, liver-protective, anti-inflammatory, anti-carcinogenic, immunomodulatory, neuritogenic and anti-bacterial properties. Wasabia japonica is a member of the Brassicacea or cruciferous vegetable family. Chemical analysis has shown the presence of a variety of bioactive compounds, such as isothiocyanates, vitamins, essential oils and minerals, but it is 6-HITC (6-methylsulfinylhexyl isothiocyanate) that has been shown to harbor the wide range of potential health benefits. I-Sabi developed by BioCell contains approximately 15,000ppm of 6-HITC, higher than other commercially available wasabi products, and is sold as a freeze-dried powder, which can be formulated into capsules, tablets and soft gels, either as a novel product or as an additional constituent.
About the Author(s)
You May Also Like